MK-0777

DB12238InvestigationalSmall molecule

MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.

Mechanism: Pharmacologically active on Gamma-aminobutyric acid receptor subunit alpha-2 and Gamma-aminobutyric acid receptor subunit alpha-3
Curator reviewed
Formula / weight: C₂₀H₂₂FN₇O · 395.442 g/mol (avg)
Code names: MK0777 · TPA-023

Resolves to

Compound

Structure

InChIKeyQKIWQBLNTSQOLY-UHFFFAOYSA-NSMILESCCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0777, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.